CY1108655T1 - ΘΕΙΟΖΟΛΙΔΙΝ-4-ΟΝΕΣ ΓΙΑ ΤΗΝ ΑΝΑΣΤΟΛΗ ΠΡΩΤΕΪΝΩΝ hYAK3 - Google Patents

ΘΕΙΟΖΟΛΙΔΙΝ-4-ΟΝΕΣ ΓΙΑ ΤΗΝ ΑΝΑΣΤΟΛΗ ΠΡΩΤΕΪΝΩΝ hYAK3

Info

Publication number
CY1108655T1
CY1108655T1 CY20081101499T CY081101499T CY1108655T1 CY 1108655 T1 CY1108655 T1 CY 1108655T1 CY 20081101499 T CY20081101499 T CY 20081101499T CY 081101499 T CY081101499 T CY 081101499T CY 1108655 T1 CY1108655 T1 CY 1108655T1
Authority
CY
Cyprus
Prior art keywords
thiosolidin
protein suspension
hyak3
hyak3 protein
hyak3 proteins
Prior art date
Application number
CY20081101499T
Other languages
English (en)
Inventor
Masaichi Hasegawa
Jun Tang
Hideyuki Sato
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of CY1108655T1 publication Critical patent/CY1108655T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε πρόσφατα εντοπισθείσες ενώσεις για την αναστολή προωτεϊνών Hyak3 και μεθόδους για την αγωγή νόσων σχετιζόμενων με την ανισορροπία ή τη μη φυσιολογική δράση των πρωτεϊνών Hyak3.
CY20081101499T 2002-11-22 2008-12-29 ΘΕΙΟΖΟΛΙΔΙΝ-4-ΟΝΕΣ ΓΙΑ ΤΗΝ ΑΝΑΣΤΟΛΗ ΠΡΩΤΕΪΝΩΝ hYAK3 CY1108655T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42838402P 2002-11-22 2002-11-22
EP03796448A EP1567112B1 (en) 2002-11-22 2003-11-18 THIAZOLIDIN-4-ONES FOR INHIBITING hYAK3 PROTEINS

Publications (1)

Publication Number Publication Date
CY1108655T1 true CY1108655T1 (el) 2014-04-09

Family

ID=32393394

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101499T CY1108655T1 (el) 2002-11-22 2008-12-29 ΘΕΙΟΖΟΛΙΔΙΝ-4-ΟΝΕΣ ΓΙΑ ΤΗΝ ΑΝΑΣΤΟΛΗ ΠΡΩΤΕΪΝΩΝ hYAK3

Country Status (31)

Country Link
US (1) US7767701B2 (el)
EP (1) EP1567112B1 (el)
JP (1) JP2006509765A (el)
KR (1) KR20050085115A (el)
CN (1) CN100579978C (el)
AP (1) AP1967A (el)
AR (1) AR045407A1 (el)
AT (1) ATE411302T1 (el)
AU (1) AU2003298693B2 (el)
BR (1) BR0316502A (el)
CA (1) CA2507256A1 (el)
CY (1) CY1108655T1 (el)
DE (1) DE60324178D1 (el)
DK (1) DK1567112T3 (el)
EA (1) EA008865B1 (el)
EC (1) ECSP055808A (el)
ES (1) ES2315566T3 (el)
HK (1) HK1083443A1 (el)
IS (1) IS2659B (el)
MA (1) MA27701A1 (el)
MX (1) MXPA05005406A (el)
MY (1) MY140132A (el)
NO (1) NO20052928L (el)
NZ (1) NZ539873A (el)
OA (1) OA12963A (el)
PL (1) PL377564A1 (el)
PT (1) PT1567112E (el)
SI (1) SI1567112T1 (el)
TW (1) TWI309648B (el)
UA (1) UA80572C2 (el)
WO (1) WO2004047760A2 (el)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1470124T3 (da) 2002-01-22 2006-04-18 Warner Lambert Co 2-(Pyridin-2-yl amino)-pyrido[2,3]pyrimidin-7-oner
MXPA06000484A (es) * 2003-07-11 2006-04-05 Warner Lambert Co Sal de isetionato de un inhibidor selectivo de la quinasa 4 dependiente de ciclina.
JP4908210B2 (ja) * 2003-07-28 2012-04-04 メルク セローノ ソシエテ アノニム Ｐｉ３キナーゼ阻害剤として使用するための２−イミノ−４−（チオ）オキソ−５−ポリシクロビニルアゾリン類
USRE43833E1 (en) 2003-11-21 2012-11-27 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
AU2004295047B2 (en) 2003-11-21 2011-03-10 Actelion Pharmaceuticals Ltd 5-(benz- (Z) -ylidene) -thiazolidin-4-one derivatives as immunosuppressant agents
JP2007523957A (ja) * 2004-02-25 2007-08-23 スミスクライン・ビーチャム・コーポレイション 新規化学化合物
AR050253A1 (es) 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
BRPI0512843A (pt) * 2004-07-01 2008-04-08 Hoffmann La Roche inibidores de quinolina
CN1984909A (zh) * 2004-07-01 2007-06-20 霍夫曼-拉罗奇有限公司 噻唑啉酮未取代的喹啉
US7253285B2 (en) * 2004-09-17 2007-08-07 Hoffmann-La Roche Inc. Thiazolinone 4-monosubstituted quinolines
US7241893B2 (en) * 2004-09-17 2007-07-10 Hoffman-La Roche Inc. Thiazolinone 2-substituted quinolines
EP1807075A2 (en) * 2004-10-12 2007-07-18 Applied Research Systems ARS Holding N.V. Pi3 kinase gamma inhibitors for the treatment of anaemia
KR20080075235A (ko) 2004-10-14 2008-08-14 에프. 호프만-라 로슈 아게 Ｃｄｋ1 항증식성 활성을 갖는 1,5-나프티리딘 아졸리디논
KR100890533B1 (ko) * 2004-10-14 2009-03-27 에프. 호프만-라 로슈 아게 Ｃｄｋ1 저해제로서의 퀴나졸리닐메틸렌 티아졸리논
AU2005293831B2 (en) * 2004-10-14 2011-01-06 F. Hoffmann-La Roche Ag Novel Azaindole thiazolinones as anti-cancer agents
US7304074B2 (en) * 2005-04-05 2007-12-04 Hoffmann-La Roche Inc. Substituted 1,5-naphthyridine azolinones
AR053602A1 (es) * 2005-05-03 2007-05-09 Smithkline Beecham Corp Compuesto de 2- arilamino -4-oxo-1,3-tiazol-5(4h)- substituido, composicion farmaceutica que lo comprende, proceso para prepararla y uso del compuesto para preparar un medicamento
WO2006127458A2 (en) * 2005-05-23 2006-11-30 Smithkline Beecham Corporation Novel chemical compounds
PE20070083A1 (es) * 2005-06-08 2007-01-27 Smithkline Beecham Corp (5z)-5-(6-quinoxalinilmetilideno)-2-[(2,6-diclorofenil)amino]-1,3-tiazol-4(5h)-ona
US20080194466A1 (en) * 2005-06-08 2008-08-14 Duffy Kevin J (5Z)-5-(6-Quinoxalinylmethylidene)-2-[(2,4,6-Trichlorophenyl)Amino]-1,3-Thiazol-4(5H)-One
TW200745066A (en) 2005-09-16 2007-12-16 Torrent Pharmaceuticals Ltd Novel PTP1B inhibitors
WO2007056683A2 (en) * 2005-11-08 2007-05-18 Smithkline Beecham Corporation Novel chemical compounds
JP2009528386A (ja) * 2006-03-02 2009-08-06 スミスクライン・ビーチャム・コーポレイション Ｐｉ３キナーゼ阻害剤として用いるためのチアゾロン
EP1993535A4 (en) * 2006-03-02 2011-04-20 Glaxosmithkline Llc THIAZOLONE AS A PI3 KINASE INHIBITOR
KR100752757B1 (ko) * 2006-04-05 2007-08-29 한국과학기술연구원 2-페닐이미노-1,3-티아졸린을 포함하는 미백 조성물
CA2650028A1 (en) * 2006-04-25 2007-11-08 The Cleveland Clinic Foundation Anti-viral agents that activate rnase l
ES2523401T3 (es) * 2006-11-23 2014-11-25 Actelion Pharmaceuticals Ltd. Intermedios de un nuevo procedimiento para la preparación de derivados de 5-benciliden-2-alquilimino-3- feniltiazolidin-4-ona
US8912340B2 (en) 2006-11-23 2014-12-16 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
US20100286041A1 (en) * 2007-03-22 2010-11-11 Smithkline Beecham Corporation (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5h)-one
CN101274918A (zh) * 2007-03-30 2008-10-01 中国科学院上海药物研究所 一类取代五元杂环化合物,其制备方法和医学用途
JPWO2010122979A1 (ja) 2009-04-20 2012-10-25 Ｓｂｉバイオテック株式会社 チアゾリジノン誘導体
WO2014021337A1 (ja) 2012-07-30 2014-02-06 国立大学法人京都大学 精神神経疾患又は悪性腫瘍に関する化合物及び医薬組成物
CA2895172C (en) 2012-08-17 2020-08-18 Actelion Pharmaceuticals Ltd Process for the preparation of|(2z,5z)-5-(3-chloro-4-((r)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-|(o-tolyl)thiazolidin-4-one and intermediate used in said process
RU2521390C1 (ru) * 2013-03-14 2014-06-27 Общество с ограниченной ответственностью "Тиацен" Производное роданина и средство для профилактики опухолевых заболеваний
US10155754B2 (en) * 2014-05-28 2018-12-18 Universitat Bern Substituted 2-imino-1,3-thiazolidin-4-ones as N-arachidonoylethanolamine cellular uptake inhibitors
CN104370852B (zh) * 2014-11-26 2016-04-20 山东大学 一种噻唑烷酮类化合物及其在制备治疗铁紊乱相关疾病药物中的应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1604530A (el) * 1967-06-06 1971-11-29
JPS5545648A (en) 1978-09-29 1980-03-31 Teikoku Hormone Mfg Co Ltd 2-formyldibenzazepin derivative and its preparation
HU188852B (en) * 1983-03-16 1986-05-28 Richter Gedeon Vegyeszeti Gyar Rt,Hu Process for producing thiazolidine derivatives active against gastric ulcer and intestinal ulcer
SU1611216A3 (ru) * 1986-12-29 1990-11-30 Пфайзер Инк (Фирма) Способ получени производных тиазолидиндиона или их фармацевтически приемлемых солей с щелочными металлами
JP2539504B2 (ja) 1987-03-11 1996-10-02 鐘淵化学工業株式会社 ヒドロキシスチレン誘導体
JPH0197926A (ja) 1987-10-09 1989-04-17 Idemitsu Kosan Co Ltd 有機非線型光学材料
DD270072A1 (de) 1988-03-14 1989-07-19 Univ Halle Wittenberg Verfahren zur herstellung von 5-aryliden- hoch 2-thiazolin-4-onen
US5306822A (en) 1988-05-25 1994-04-26 Warner-Lambert Company Arylmethylenyl derivatives of oxazolidinone
US5145753A (en) 1989-09-12 1992-09-08 Mitsubishi Jukogyo Kabushiki Kaisha Solid electrolyte fuel cell
US5053420A (en) 1989-10-13 1991-10-01 Pershadsingh Harrihar A Thiazolidine derivatives for the treatment of hypertension
GB9004483D0 (en) 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
US5143928A (en) 1990-03-27 1992-09-01 Warner-Lambert Company 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
JPH052200A (ja) 1990-09-28 1993-01-08 Toshiba Corp 有機非線形光学材料
ATE179615T1 (de) * 1991-02-08 1999-05-15 Pro Neuron Inc Oxypurin-nukleoside und seine artverwandten, und acylderivate davon, zur verbesserung der hämatopoese
JP3155050B2 (ja) 1991-02-28 2001-04-09 富士通株式会社 荷電粒子ビームを用いた露光方法
EP0554834B1 (en) 1992-02-03 1998-06-03 Fuji Photo Film Co., Ltd. Process for dispersing dyestuff and silver halide photographic material containing dyestuff
JP2835246B2 (ja) 1992-06-02 1998-12-14 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
CZ181493A3 (en) 1992-09-10 1994-03-16 Lilly Co Eli The use of rhodanine derivative for the preparation of a pharmaceutical composition reducing level of sugar in blood and for treating alzheimer's disease
EP0587230B1 (en) 1992-09-11 2003-11-26 Agfa-Gevaert Photographic element containing a filter dye for rapid processing applications
EP0587229B1 (en) 1992-09-11 2002-05-08 Agfa-Gevaert Photographic element containing a filter dye for rapid processing applications
JPH06128234A (ja) 1992-10-19 1994-05-10 Fuji Photo Film Co Ltd 不斉炭素原子を有する化合物およびそれからなる非線形光学材料
US5554767A (en) 1993-05-21 1996-09-10 Warner-Lambert Company Alpha-mercaptoacrylic acid derivatives having calpain inhibitory activity
US6251928B1 (en) 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
JP3871354B2 (ja) 1994-07-29 2007-01-24 株式会社フジモト・コーポレーション 新規な２−（ｎ−シアノイミノ）チアゾリジン−４−オン誘導体
JPH08109176A (ja) 1994-10-07 1996-04-30 Torii Yakuhin Kk イソローダニンｎ酢酸誘導体
IL117208A0 (en) 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
US5618835A (en) 1996-02-01 1997-04-08 The Procter & Gamble Company Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
JPH09255669A (ja) 1996-03-22 1997-09-30 Hisamitsu Pharmaceut Co Inc 新規なベンジリデン誘導体
US5958957A (en) 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
UY24886A1 (es) 1997-02-18 2001-08-27 Smithkline Beecham Plc Tiazolidindiona
US6011031A (en) 1997-05-30 2000-01-04 Dr. Reddy's Research Foundation Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them
US6211209B1 (en) * 1997-08-08 2001-04-03 Warner-Lambert Company Method of inhibiting connective tissue degradation
WO1999059586A1 (en) 1998-05-19 1999-11-25 Regents Of The University Of California Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
WO2000018748A1 (en) 1998-09-30 2000-04-06 Roche Diagnostics Gmbh Rhodanine derivatives for the treatment and prevention of metabolic bone disorders
US6221613B1 (en) 1998-12-31 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
US6689491B1 (en) 1999-02-08 2004-02-10 Fuji Photo Film Co., Ltd. Luminescent device material, luminescent device using the same, and amine compound
AU6062900A (en) 1999-07-01 2001-01-22 Geron Corporation Substituted indole compounds and their use for the treatment of cancer
JP2001348520A (ja) 2000-04-03 2001-12-18 Fuji Photo Film Co Ltd メチン化合物、固体微粒子分散物、インクジェット用記録液、およびインクジェット記録方法
EP1299362A4 (en) 2000-07-05 2004-11-03 Synaptic Pharma Corp SELECTIVE RECEPTOR ANTAGONISTS OF MELANINE CONCENTRATING HORMON-1 (MCH1) AND THEIR USE
US6410734B1 (en) 2000-07-17 2002-06-25 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
DE10115227A1 (de) 2001-03-28 2002-12-19 Bayer Ag Optischer Datenträger enthaltend in der Informationsschicht eine lichtabsorbierende Verbindung mit mehreren chromophoren Zentren
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
AR037714A1 (es) * 2001-12-06 2004-12-01 Maxia Pharmaceuticals Inc Derivados de tiazolidinona y oxazolidinona 2-sustituidos para la inhibicion de fosfatasas y el tratamiento de cancer

Also Published As

Publication number Publication date
US7767701B2 (en) 2010-08-03
JP2006509765A (ja) 2006-03-23
EA008865B1 (ru) 2007-08-31
MA27701A1 (fr) 2006-01-02
TW200418819A (en) 2004-10-01
EP1567112B1 (en) 2008-10-15
BR0316502A (pt) 2005-10-04
CA2507256A1 (en) 2004-06-10
CN100579978C (zh) 2010-01-13
KR20050085115A (ko) 2005-08-29
EA200500856A1 (ru) 2005-10-27
SI1567112T1 (sl) 2009-02-28
ATE411302T1 (de) 2008-10-15
WO2004047760A2 (en) 2004-06-10
UA80572C2 (en) 2007-10-10
CN1742010A (zh) 2006-03-01
IS2659B (is) 2010-08-15
HK1083443A1 (en) 2006-07-07
MY140132A (en) 2009-11-30
AR045407A1 (es) 2005-10-26
DE60324178D1 (de) 2008-11-27
EP1567112A2 (en) 2005-08-31
NO20052928L (no) 2005-08-17
DK1567112T3 (da) 2009-02-09
PT1567112E (pt) 2009-01-08
TWI309648B (en) 2009-05-11
AP1967A (en) 2009-03-10
MXPA05005406A (es) 2005-08-03
IS7879A (is) 2005-06-02
AU2003298693B2 (en) 2010-09-30
OA12963A (en) 2006-10-13
US20060293338A1 (en) 2006-12-28
EP1567112A4 (en) 2006-11-15
AU2003298693A1 (en) 2004-06-18
WO2004047760A3 (en) 2004-10-21
ES2315566T3 (es) 2009-04-01
NZ539873A (en) 2008-09-26
PL377564A1 (pl) 2006-02-06
ECSP055808A (es) 2005-09-20
NO20052928D0 (no) 2005-06-15
AP2005003304A0 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
CY1108655T1 (el) ΘΕΙΟΖΟΛΙΔΙΝ-4-ΟΝΕΣ ΓΙΑ ΤΗΝ ΑΝΑΣΤΟΛΗ ΠΡΩΤΕΪΝΩΝ hYAK3
CY1111225T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
CY1119601T1 (el) Προαγωγεις αποπτωσης
CY1116385T1 (el) Αντινοηματικη διαμορφωση της εκφρασης της απολιποπρωτεινης β
CY1110177T1 (el) Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης
CY1110530T1 (el) Ανοσοσφαιρινες που εξουδετερωνουν το nogoa για τη θεραπεια νευρολογικων ασθενειων
CY1112267T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης ns3-σερινης του ιου ηπατιτιδας c
ATE267830T1 (de) Als cox-hemmer verwendbare sulfonylphenylpyrazol- verbindungen
ATE411805T1 (de) Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
ATE513917T1 (de) Bakterielle expression von proteaseinhibitoren und varianten davon
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
HUP0402029A2 (hu) Peptidalapú multimer célzott kontrasztanyagok
CY1107871T1 (el) Παραγωγα πυριμιδινης και η χρηση τους ως ρυθμιστων cb2
CY1109219T1 (el) Ινδολο, αζαινδολο και σχετικα ετεροκυκλικα αμιδοπιπεραζινο παραγωγα
ATE361067T1 (de) Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
DE602004017736D1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
ATE470672T1 (de) Verwendung von cupredoxin-proteine für krebstherapie
NO20055309L (no) Slurp-1 samrnensetninger og fremgangsmater for anvendelse derav
ATE292801T1 (de) Verfahren zum screening von inhibitoren von asp2
EA200501528A1 (ru) Применение кластерина для лечения и/или профилактики периферических неврологических заболеваний
ATE410235T1 (de) Behandlung von ballastwasser
DE60325194D1 (de) Methoden zur verwendung von lamellaren körpern für therapeutische zwecke
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie